Anika Therapeutics (ANIK) Equity Average (2011 - 2026)

Anika Therapeutics (ANIK) has 16 years of Equity Average data on file, last reported at $138.7 million in Q1 2026.

• Equity Average for Q1 2026 came in at $138.7 million, down 8.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $138.7 million (down 8.27% YoY), and the FY2025 annual result was $148.7 million, down 18.78% from the prior year.
• Equity Average fell to $138.7 million in Q1 2026 per ANIK's latest filing, from $145.1 million in the prior quarter.
• Over five years, Equity Average peaked at $286.4 million in Q1 2022 and troughed at $138.7 million in Q1 2026.
• A 5-year average of $219.2 million and a median of $210.4 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average advanced 4.34% in 2022, then tumbled 30.84% in 2024.
• A 5-year view of Equity Average shows it stood at $285.2 million in 2022, then declined by 15.38% to $241.4 million in 2023, then plunged by 30.84% to $166.9 million in 2024, then retreated by 13.05% to $145.1 million in 2025, then retreated by 4.45% to $138.7 million in 2026.
• Business Quant data shows ANIK's Equity Average at $138.7 million in Q1 2026, $145.1 million in Q4 2025, and $147.2 million in Q3 2025.